Document is current
Any future updates will be listed below
-
Authors
da Cruz Guedes, Erika
Erustes, Adolfo Garcia
Leão, Anderson H. F. F.
Carneiro, César Alves
Abílio, Vanessa C.
Zuardi, Antonio W.
Hallak, Jaime Eduardo C.
Crippa, José Alexandre
Bincoletto, Claudia
Smaili, Soraya S.
Reckziegel, Patrícia
Pereira, Gustavo J. S.
-
Funding
Funding for this research was provided by:
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (001)
Fundação de Amparo à Pesquisa do Estado de São Paulo (2020/08840-1, 2019/02821-8, 2017/10863-7)
- License Information
-
More Information
Article History
Received: 5 September 2022
Revised: 27 February 2023
Accepted: 1 March 2023
First Online: 25 March 2023
Declarations
:
: JAC reported receiving grants from the National Institute of Translational Science and Technology in Medicine and personal fees from the National Council for Scientific and Technological Development (CNPq 1A) during the conduct of the study, being a co-owner of a patent for fluorinated cannabidiol compounds (licensed to Phytecs) and having a patent pending for a cannabinoid-containing oral pharmaceutical composition outside the submitted work. JAC is a consultant and/or has received speaker fees and/or sits on the advisory board and/or receives research funding from Janssen-Cilag, Torrent, GreenCare, PurMed Global, BioSynthesis Pharma Group (BSPG), and Prati-Donaduzzi. JAC reported receiving grants from FAPESP. The other authors declare no conflicts of interest.
